Alessandro D. Santin MD
Professor of Obstetrics, Gynecology, and Reproductive Sciences; Clinical Research Program Leader, Gynecologic Oncology Program, Yale Cancer Center
Departments & Organizations
Yale Medical Group
Cancer Center, Yale: Gynecologic Oncology Program | Cancer - Uterus | Molecular Virology
Obstetrics, Gynecology & Reproductive Sciences: Gynecologic Oncology | Ovarian Cancer Program, Early Detection | Cancer Biology Group | Women's Reproductive Health Research Career Development Center
Mutational landscape of gynecolocic tumors; Therapeutic vaccine development for gynecologic malignancies; Tumor immunology; Immunotherapy; Tumor angiogenesis; Radiation biology; Experimental therapeutics in gynecologic oncology more...
- M.D., University of Brescia School of Medicine, 1989
- Bellone S. Roque D. Cocco E. Gasparrini S. Bortolomai I. Buza N. Abu-Khalaf M. Silasi DA. Ratner E. Azodi M. Schwartz PE. Rutherford TJ. Pecorelli S. Santin AD. Downregulation of membrane complement inhibitors CD55 and CD59 by siRNA sensitises uterine serous carcinoma overexpressing Her2/neu to complement and antibody-dependent cell cytotoxicity in vitro: implications for trastuzumab-based immunotherapy. British Journal of Cancer. 106(9):1543-50, 2012
- Santin AD, Sill MW D. McMeekin D.S, Leitao MM, Jubilee Brown J, Sutton GP, Van Le L,Griffin P, Boardman CH, Phase II trial of Cetuximab in the Treatment of Persistent or Recurrent Squamous or Non-Squamous Cell Carcinoma of the Cervix: A Gynecologic Oncology Group Study. Gynecol Oncol 122(3):495-500, 2011.
- Casagrande C, Cocco E, Bellone S, Richter CE, Bellone M, Todeschini P, Siegel E, Varughese J, Silasi D-A, Azodi M, Rutherford TJ, Pecorelli S, Schwartz PE, Santin AD. Eradication of Chemotherapy-Resistant CD44+ Human Ovarian Cancer Stem cells in Mice by Intraperitoneal Administration of Clostridium Perfringens-Enterotoxin (CPE). Cancer. 117(24):5519-28, 2011.